AZTA
HealthcareAzenta, Inc. · Medical - Instruments & Supplies · $930M
What is Azenta, Inc.?
Azenta, Inc. is a small-cap life sciences company specializing in sample management and exploration solutions. It serves pharmaceutical, biotechnology, and research customers across North America, Europe, China, and the broader Asia Pacific region.
Azenta operates through two segments: Life Sciences Products and Life Sciences Services. The Products segment delivers automated cold sample management systems, sample preparation equipment, consumables, and instruments that support research workflows. The Services segment offers sample storage, genomic sequencing, gene synthesis, biospecimen procurement, integrated cold chain solutions, and laboratory analysis — helping pharmaceutical and biotech clients manage samples from early discovery through drug development.
Formerly known as Brooks Automation, Inc., Azenta adopted its current name in December 2021 and is headquartered in Burlington, Massachusetts.
- Automated cold sample management and storage systems
- Sample preparation and handling instruments
- Genomic sequencing and gene synthesis services
- Integrated cold chain and informatics solutions
- Biospecimen procurement and laboratory analysis services
Is AZTA a Good Stock to Buy?
UQS Score rates AZTA as Below Average overall.
The most notable bright spot in Azenta's profile is its Risk pillar, which scores Strong — suggesting the balance sheet carries relatively low financial risk compared to many small-cap peers. The Valuation pillar also registers as Good, meaning the stock does not appear significantly stretched on a price basis relative to its fundamentals.
Both the Quality and Moat pillars register as Weak, pointing to challenges around profitability consistency and durable competitive positioning. The Growth pillar sits at Neutral, reflecting an uninspiring near-term expansion trajectory.
Sign up for a Pro account to see the exact pillar breakdown and the full financial metrics behind each rating. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AZTA pay dividends?
No — Azenta, Inc. does not currently pay a dividend.
Azenta does not currently pay a dividend. For a company operating in the life sciences tools and services space, capital is typically directed toward research infrastructure, service capacity, and potential acquisitions rather than shareholder distributions. Investors seeking income from this holding would need to look elsewhere, as reinvestment remains the primary capital allocation approach.
When does AZTA report earnings?
Azenta reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results reflect the mixed environment facing life sciences tools providers, with demand from pharmaceutical and biotech customers remaining uneven. Revenue trends across both the Products and Services segments have been subject to broader industry spending cycles.
For the most recent quarter's results and guidance commentary, visit Azenta's investor relations page directly.
AZTA Price History
-74.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Azenta, Inc.?
Based on Azenta, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AZTA Long-term Outlook
Azenta's fundamental outlook is shaped by a Neutral Growth profile and a Strong Risk rating. The company is not positioned as a high-velocity grower, but its relatively conservative financial structure provides a degree of stability. The Weak Quality and Moat ratings suggest that translating revenue into consistent profitability remains a work in progress, and competitive differentiation in the life sciences services market will be a key factor in any longer-term improvement.
Growth drivers
- Expanding demand for genomic sequencing and biospecimen services from biopharma customers
- Growth in automated sample management as research workflows scale globally
- International expansion across Asia Pacific and European life sciences markets
Key risks
- Weak profitability profile may limit reinvestment capacity and margin recovery
- Competitive pressure in life sciences tools and services from larger, better-resourced players
- Biopharma spending cycles can create lumpy demand across both operating segments
AZTA vs Peers
Azenta operates in a competitive life sciences tools and services landscape alongside a range of specialized peers.
Anbio Biotechnology focuses on rapid diagnostic testing products, operating in a different niche of the life sciences market than Azenta's sample management and storage focus.
STAAR Surgical concentrates on implantable lens technology for vision correction, representing a medical device angle distinct from Azenta's laboratory and sample services model.
BioLife Solutions provides biopreservation media and cold chain products, overlapping with Azenta's cold sample management offerings but with a narrower product-focused business model.
Frequently Asked Questions
What does Azenta do?
Azenta provides life science sample management and exploration solutions. Its two segments cover automated cold storage systems, sample preparation instruments, and consumables on the products side, plus genomic sequencing, gene synthesis, biospecimen procurement, and cold chain services on the services side. Customers include pharmaceutical companies, biotech firms, and research institutes worldwide.
Does AZTA pay dividends?
Azenta does not currently pay a dividend. The company operates in a capital-intensive life sciences services environment where resources are directed toward infrastructure and growth initiatives rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does AZTA report earnings?
Azenta follows a standard quarterly earnings cadence for US-listed companies. Specific upcoming report dates are not covered by our data source. For confirmed dates and the latest results, check Azenta's official investor relations page.
Is AZTA a good stock to buy?
UQS Score rates AZTA as Below Average overall. The Risk pillar is Strong and Valuation is Good, but Quality and Moat both register as Weak, and Growth is Neutral. Whether that profile suits a particular investor depends on their own criteria. The full pillar breakdown is available to Pro members.
Is AZTA overvalued?
The UQS Valuation pillar for AZTA is rated Good, suggesting the stock is not trading at a significant premium relative to its fundamentals. However, valuation alone does not determine investment quality — the Weak Quality and Moat ratings are important context. See the complete analysis by signing up for a Pro account.
How does AZTA compare to its competitors?
Among peers like BioLife Solutions, STAAR Surgical, and Anbio Biotechnology, Azenta is distinguished by its dual-segment model spanning both automated sample management products and comprehensive laboratory services. Its Strong Risk rating stands out, though its Weak Moat suggests competitive differentiation remains a challenge relative to more specialized peers.
What is AZTA's market cap bracket?
Azenta is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but also tends to carry higher volatility and less analyst coverage than large- or mega-cap peers in the healthcare and life sciences sector.
Who founded Azenta?
Azenta traces its roots to Brooks Automation, Inc., which was founded in 1978. The company rebranded to Azenta, Inc. in December 2021 following a strategic shift toward life sciences. Detailed founding history is widely available through the company's public filings and investor relations materials.
Is AZTA a long-term quality indicator?
From a long-term quality perspective, AZTA's UQS profile presents a mixed picture. The Strong Risk rating and Good Valuation provide a degree of stability, but the Weak Quality and Moat pillars suggest the company has not yet established the durable profitability or competitive advantages typically associated with high-quality long-term holdings.
What is the main competitive advantage of Azenta?
Azenta's integrated approach — combining automated cold sample management hardware with a broad suite of laboratory and genomic services — creates a degree of customer stickiness within research workflows. However, the UQS Moat pillar rates this positioning as Weak, indicating the advantage may not yet be deeply entrenched relative to sector peers.
What sector does AZTA belong to?
Azenta operates in the Healthcare sector, specifically within the life sciences tools and services industry. It serves pharmaceutical companies, biotechnology firms, biorepositories, and academic research institutes, making it sensitive to trends in biopharma R&D spending and scientific research funding cycles.
Is AZTA a growth stock or value stock?
Based on UQS pillar labels, AZTA sits in an in-between position. The Growth pillar is Neutral, suggesting neither strong expansion momentum nor contraction, while the Valuation pillar is Good, indicating the price is not elevated. It does not fit cleanly into either the classic growth or deep-value category at this time.
Unlock Full AZTA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare AZTA against sector peers side by side
- ✓See the detailed Quality and Moat breakdown
- ✓Get the full Risk and Valuation scoring rationale
- ✓Track score changes over time with Pro alerts
Pro Analysis
AZTA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 38.6 | 13.0 | 21.0 | 43.9 | 80.8 | 61.6 | -0.3 |
| May 22, 2026 | 38.9 | 13.0 | 21.0 | 43.9 | 80.8 | 63.1 | -0.2 |
| May 21, 2026 | 39.1 | 13.0 | 21.0 | 43.9 | 80.8 | 64.5 | -0.1 |
| May 20, 2026 | 39.2 | 13.0 | 21.0 | 43.9 | 80.8 | 65.6 | -0.2 |
| May 19, 2026 | 39.4 | 13.0 | 21.0 | 43.9 | 80.8 | 66.4 | 0.0 |
| May 17, 2026 | 39.4 | 13.0 | 21.0 | 43.9 | 80.8 | 66.7 | -0.1 |
| May 16, 2026 | 39.5 | 13.0 | 21.0 | 43.9 | 80.8 | 67.6 | -0.1 |
| May 15, 2026 | 39.6 | 13.0 | 21.0 | 43.9 | 80.8 | 67.9 | +0.1 |
| May 14, 2026 | 39.5 | 13.0 | 21.0 | 43.9 | 80.8 | 67.6 | +0.4 |
| May 13, 2026 | 39.1 | 12.2 | 21.0 | 43.9 | 80.8 | 66.2 | +0.1 |
AZTA — Pillar Breakdown
Quality
— 13.0/100 (25%)Azenta, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 43.9/100 (20%)Azenta, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 80.8/100 (15%)Azenta, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 63.0/100 (15%)Azenta, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 21/100 (25%)Azenta, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AZTA.
Score Composition
Financial Data
More Stock Analysis
How is the AZTA UQS Score Calculated?
The UQS (Unified Quality Score) for Azenta, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Azenta, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Azenta, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.